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Abstract
In this manuscript, we modulate the binding properties of estrogen receptor protein by rationally modifying the amino acid
composition of its ligand binding domain. By combining sequence alignment and structural analysis of known estrogen
receptor-ligand complexes with computational analysis, we were able to predict estrogen receptor mutants with altered
binding properties. These predictions were experimentally confirmed by producing single point variants with up to an order
of magnitude increased binding affinity towards some estrogen disrupting chemicals and reaching an half maximal
inhibitory concentration (IC50) value of 2 nM for the 17a-ethinylestradiol ligand. Due to increased affinity and stability,
utilizing such mutated estrogen receptor instead of the wild type as bio-recognition element would be beneficial in an
assay or biosensor.
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Introduction
The estrogen receptor protein (ER) is a member of the
superfamily of nuclear receptors [1–3] whose natural ligand is
the hormone 17b-estradiol. Estrogen receptors are present in all
vertebrates, highlighting the importance of the ER signal pathway.
Binding of 17b-estradiol to ER activates a signaling pathway that
regulates several key biological processes such as reproduction,
embryonic development [4] and homeostasis [5–7]. There are two
distinct estrogen receptor genes, resulting in two subtypes of
estrogen receptors (ERa and ERb) that differ in tissue distribution
and ligand preference [8]. In addition to the classical ER ligand
inducible transcription activity, there are mounting evidence that
ER can act as extra-nuclear activator, independent of gene
expression and protein synthesis [9]. These activities are linked to
the ERs residing in, or near, the plasma membrane and seem to be
involved in breast cancer development and progression[10].
ER is composed by three structural domains: a modulating
domain with ligand-independent transactivation function, a DNA-
binding domain (DBD) and a ligand binding domain (LBD) [11–
13]. The amino acid sequences of the LBD of estrogen receptors
from several species are available and they indicate that the core of
this domain is highly conserved from mammals to fish [14,15].
Even if sequence homology in the ligand binding domain is
high, several studies indicate that estrogenic compounds may have
different affinities for ER subtypes [16] and for different organisms
[17–19].
Besides the natural hormone ligands, a large variety of chemical
compounds (collectively referred to as endocrine disrupting
chemicals, EDCs) can bind to ERs [20]. Many EDCs have been
shown to be toxic for animals and humans due to their ability to
interfere with the normal function of ER, leading to many adverse
effects such as reproductive problems, hormonal and immune
system malfunctions, several types of cancer [21–23] and
feminization in some fish and amphibians [24–31].
Thousands of EDCs, belonging to various chemical classes such
as drugs, pesticides, byproducts of plastic and healthcare
industries, are commonly present in the environment as a result
of industrial, agricultural and household waste [32]. EDCs may
also arise from the degradation pathway of otherwise harmless
compounds. They are of particular concern due to their wide
environmental dispersion and to their tendency to bio-accumulate
[33]. It is not possible to classify a compound as an EDC, and thus
potentially dangerous, based on its chemical properties alone;
instead, the ability of such compound to bind to ER and alter its
function should be investigated. Monitoring the presence of a vast
number of different EDCs in soil and water and studying their
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biochemical effect on ER is considered one of the key current
challenges for ensuring healthy ecosystems in both developed and
in-development countries.
For these reasons, analytical methods that exploit ER as a bio-
recognition element to detect the presence of EDCs are
particularly attractive: if a chemical binds to ER in the assay,
then it means that it can potentially interfere with the hormone
signaling pathways and thus be toxic.
X-ray structures have shown that the human ER binds ligands
in a highly hydrophobic pocket that can accommodate EDCs of
different sizes and chemical properties [34–36]. Due to the high
sequence identity, it is likely that the general conformation of the
ER ligand binding site is conserved; however, local structural
differences and a certain degree of conformational flexibility have
to be present to account for the different properties and affinities of
EDC compounds. These differences may, at least in principle, be
exploited for the rational design of modified receptors capable of
recognizing classes of EDCs with different affinity and selectivity.
In this manuscript, we aimed to modulate the binding
properties of the estrogen receptor protein by rationally modifying
the amino acid composition of the ligand binding domain. By
combining sequence alignment and structural analysis of known
ER-ligand complexes with computational analysis, we were able to
predict single point variants of the estrogen receptor ligand
binding domain (ERa
LBD) with altered binding properties with
respect to the wild type ER ligand binding domain (wt-ERa
LBD).
These predictions were experimentally confirmed by producing
and characterizing the most relevant recombinant ERa
LBD
variants. In particular, we were able to generate a single point
ER mutant with a 6-fold increased binding affinity towards some
EDCs (bisphenolic compounds), reaching i.e. an IC50 value of
2 nM for 17a-ethinylestradiol ligand. 17a-Ethinylestradiol is an
orally bio-active hormone and one of the most commonly used
medications, identified as an emerging aquatic pollutant due to its
bio-accumulation in surface waters [37,38]. Due to the increased
affinity of one of our ER variants for this and other compounds,
utilizing such mutated ER instead of the wt-ERa
LBD as bio-
recognition element in an assay or biosensor would result in
increased sensitivity.
Results
Sequence and structural analysis of Estrogen Receptors
The full-length Estrogen Receptor a (ERa) is a protein of
approximately 65 kDa formed by several independent structural
domains (Figure 1A). The so-called Ligand Binding Domain
(LBD, approximately 25 kDa) is necessary and sufficient to bind
either the natural ligand (17b-estradiol) or EDCs.
Comparison of the amino acid sequence of several species shows
that the LBD (corresponding to the polypeptide fragment 303-547)
is highly conserved. The polypeptide fragment 303-547 of the
human ERa has been thus cloned (with the addition of a His6 N-
terminal sequence for affinity purification) into the expression
vector pET21a(+) to produce the recombinant protein used in
these studies: ERa (303-547), or in short ERa
LBD.
X-ray crystallography structures have shown the region of the
human ERa
LBD responsible for EDCs binding [34–36]. EDCs
bind to a highly hydrophobic pocket that can accommodate
compounds with different sizes and chemical properties. The
residues forming the ligand binding pocket are almost universally
conserved but some intriguing differences are nonetheless present.
As a first step we defined an ERa
LBD residue as belonging to the
binding pocket if any of its atoms are within 6 A˚ of the ligand in
any of the x-ray structures of human ER ligand binding domain
bound to different EDCs of various sizes. The 6 A˚ distance cut-off
is rather large in order to obtain a conservative description of the
binding pocket. This identifies a set of 25 non-contiguous amino
acids (human ERa numbering), shown in Figure 1B.
We then compared the sequence alignment of these residues in
more than 200 ER proteins from different species. Most residues
have 100% conservation with a few exceptions noted below
(Figure 1B). Position 349 is predominantly occupied by a
methionine (M), but it can also be leucine (L) as in the case of
the human protein or, more rarely, valine (V). All three possible
variants in position 349 (M, L, V) have aliphatic side chains with
similar size and properties. Computational simulations suggest that
these mutations should not have a great impact on the binding
pocket.
Residue 421 is usually a methionine (M) but it is replaced by
isoleucine (I) or leucine (L) in several species, a rather conservative
mutation once again. In 22 of the analyzed ER sequences,
however, residue 421 is a phenylalanine (F), which is still
hydrophobic but has properties not shared by the other amino
acids. First of all, F421 introduces an aromatic residue in the
binding pocket and it may increase the affinity of the receptor for
aromatic compounds such as, for instance, bisphenols. In second
order, introducing the large phenylalanine side chain may reduce
the size of the ligand binding pocket. The F421-ERa
LBD, thus,
may be unable to bind large EDCs due to steric clashes with the
phenylalanine aromatic ring. Alternatively, structural changes in
the binding pocket may be required to accommodate large EDCs.
Less frequent and conservative amino acid substitutions are also
present at position 350, 351, 522, and 525.
Computational design of mutant ER receptors
To rationally design ER receptors with altered binding
properties towards different classes of EDCs, we predicted the
structural effects of introducing single point mutations in the ERa
binding pocket. The first candidates for virtual mutations analysis
were those amino acids that exist as natural variants in different
species. This strategy should increase the probability that the
resulting mutated protein is functional and properly folded. To this
end, the most interesting starting point seemed to be position 421,
for which there are existing natural variants carrying either M, L,
I, or F amino acids, which provide opportunities for both
conservative (M421L, M421I) and non-conservative (M421F)
mutations. We used computational approaches to predict: the
structure of each ER mutant of interest (M421F, M421I, M421L);
the structure of the complexes between each mutant and either the
natural 17b-estradiol ligand or some selected EDCs.
To predict the structure of the unbound, mutated ERa
LBD we
either i) replaced the side chain of the interested residue and used
rotamer libraries to define its new orientation or ii) predicted the
whole protein structure by homology modeling. No significant
structural differences were found between wt and mutated ER
when unbound. This is not surprising, since even the largest side-
chain (F421) can be accommodated in the existing binding pocket
if this is not occupied by ligands.
We then moved to predict the three-dimensional structure of
the complex between wild type and mutated ER and selected
EDC ligands. As a first test to assess the accuracy of our docking
approach, we predicted the structures of 17b-estradiol and
bisphenol-A with human wt-ER (Figure 2A). X-ray structures of
each of these are available and the computational results were in
very good agreement with the experimental data, supporting the
idea that computational predictions can be used to assess the
impact of the mutations. We then proceeded to predict the
structure of the above mentioned compounds in complex with the
Rational Modification of Estrogen Receptor
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ER mutants. We used two different docking algorithms with either
rigid or flexible docking options. In the latter case the side-chains
and backbone of the protein are allowed to move, trying to
accommodate local structural rearrangements upon EDC binding.
It should be pointed out, however, that large changes in the ER
structure cannot be correctly simulated and would not be detected
by this approach. No significant differences amongst the various
procedures were noted.
Ligand binding to M421F-ERa
LBD
We suspected that introduction of an aromatic ring in the
binding pocket (M421F mutant) could increase the affinity of ER
for aromatic compounds. Indeed, computational docking predic-
tions suggest that bisphenol-A bound to M421F-ERa
LBD changes
in comparison to its complex with wt-ERa
LBD, bringing one of its
aromatic rings closer to the ring of F421 (Figure 2B), something
that cannot be achieved with wt-ERa
LBD (Figure 2A) This may
result in a higher affinity of bisphenol-A for M421F-ERa
LBD,
either due to the formation of direct aromatic stacking interactions
or as a consequence of the increased aromatic character of the
mutated binding pocket.
Phenolic compounds linked to bulkier aliphatic side chains (e.g.
4-nonylphenol) are somehow different: although they can fit in the
mutated ligand binding pocket just like wt-ERa
LBD, their larger
size does not allow their aromatic ring to get closer to M421F as it
happens to bisphenol-A (Figure 2C). We wouldn’t expect,
therefore, an increased affinity of M421F-ERa
LBD for these
compounds.
The natural ER ligand, 17b-Estradiol, has an aromatic ring that
may be favorably affected by the M421F substitution in a similar
way to bisphenols (Figure 2D). However, the aromatic ring is far
away from M421 in the wt-ERa
LBD experimental structure; if
F421 would maintain the same conformation, it would be unable
to achieve direct aromatic stacking interactions with 17b-Estradiol.
On the other hand, if 17b-estradiol would bind to F421 in a
position different from the one it has in wt-ERa
LBD, then the
M421F-ERa
LBD could have increased affinity for 17b-estradiol
due to favorable interactions between the aromatic rings.
Computational docking of 17b-estradiol in complex with
M421F-ERa
LBD shows a binding conformation comparable to
that of wt-ERa
LBD in the models considered more energetically
favorable by the algorithm (Figure 2D). Models deemed to be less
stable, however, position the aromatic ring of 17b-estradiol in
proximity of the ring of F421, which may result in increased
binding affinity. Since computational algorithms are notoriously
unreliable at correctly identifying energetically favored ligand
positions within the same binding region, it can be suggested that
17b-estradiol can fit in the mutated binding pocket with its
Figure 1. Schematic representation of the structural domains of ER protein. A) A cartoon representation of the three-dimensional structure
of the ligand binding domain is shown, as well as its sequence. Residues belonging to the ligand binding pocket are shown in red in both the
structure and sequence. Residues highlighted in yellow belong to the histidine tag, residues in light blue encompass the ligand binding domain. B)
Degree of conservation for residues of the ligand binding pocket among the analyzed ER sequences. Full bars correspond to 100% conservation.
doi:10.1371/journal.pone.0102658.g001
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aromatic ring close to F421. Whether this conformation is
preferred in vivo remains to be seen.
Finally, computational docking of tamoxifen (a commercial
drug that binds to ER) shows no appreciable differences between
wt-ERa
LBD and M421F-ERa
LBD. Although tamoxifen is much
larger than the natural 17b-estradiol ligand, x-rays structure has
shown it to only partially occupy the ligand binding pocket [34],
which can thus probably be restricted without affecting the ligand.
Production and characterization of ER mutants
Structural and computational analysis of the wt-ERa
LBD
binding pocket suggested that mutations in position 421 could
have a significant influence on the affinities of different EDCs
towards the ER. In order to verify this hypothesis by experimental
measures of binding affinity we generated three ER mutants:
M421F-ERa
LBD, M421I-ERa
LBD, and M421L-ERa
LBD.
High yield of proteins, ranging from 25 to 30 mg/L of liquid
culture, were obtained. Following a single purification step by
affinity chromatography pure proteins samples were obtained, as
shown in the SDS-PAGE of the various ER mutants (inset in
Figures 3A, B and C).
CD spectroscopy confirms that the mutants are properly folded
(Figures 3B and 3C) and comparable to wt-ERa
LBD (Figure 3A).
The percentage of secondary structure elements were calculated
using standard algorhythms provided by the online DichroWeb
service [39]. The calculations showed the presence of 54% a-
helical secondary structure for all the wild-type and the mutants
which reflects well the secondary structure elements derived from
Figure 2. Computational docking models of ligands in the ER binding pocket. The protein backbone is shown as grey cartoon; ligands and
side chain of residue 421 are shown as sticks; hydrogen atoms are not shown for clarity. M421F-ERa
LBD mutant bound to bisphenol-A (orange in B), 4-
nonylphenol (green in C) and 17b-estradiol (red in D). In contrast to the wt-ERa
LBD (shown in A with bisphenol A), the aromatic ring of the F421
mutated ER may increase the affinity for the ligands either by direct stacking interactions or by increasing the aromatic content of the ligand binding
pocket; no steric clashes are created by the incorporation of this larger side chain.
doi:10.1371/journal.pone.0102658.g002
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the available three dimensional structure of wt-ERa
LBD (PDB:
1ERE).
The thermal stability of the different ERs was assessed by
following the protein thermal unfolding between 25 and 90uC with
CD spectroscopy (Figures 3D, 3E and 3F). The unfolding process
is not reversible: by cooling back the samples to 25uC only around
50% of the original secondary structure of the protein is recovered
(data not shown). By fitting the experimental data with a
Boltzmann-type equation it was possible to calculate melting
temperature (Tm) values of 59.561.5uC, 65.861.4uC, and
61.561.3uC for the wt-ERa
LBD, M421F-ERa
LBD, and M421I-
ERa
LBD proteins, respectively.
The M421L-ERa
LBD mutant had the same characteristics of
purity, secondary structure and melting temperature of M421I-
ERa
LBD (data not shown).
The melting temperature of the wt-ERa
LBD receptor is about
20uC higher than that previously reported for the full-length ERa
protein [40,41]. The isolated ligand binding domain, in other
words, appears more stable than the full length ER protein. It is
also interesting to note that it is reported that the CD signal
decreases sharply as the temperature increases from 20 to 30uC
and then increases gradually from 30 to 70uC. We, instead,
observe a single transition sigmoidal trend. Our results also
indicate that the M421F-ERa
LBD mutant is significantly more
stable than the wt-ERa
LBD.
Competitive binding assay
The PolarScreen assay was used to test the ligand binding
affinity of wt-ERa
LBD and its mutants towards different classes of
estrogen disrupting compounds. The tested chemical compounds
(shown in Figure 4) were: the natural ligand 17b-estradiol; its close
analog 17a-ethynilestradiol (chosen since it is an emerging
pollutant [42]); tamoxifen, a commercial drug antagonist often
detected in surface waters [43]; and three other compounds with
known estrogen disrupting activity and significant presence in the
environment, bisphenol-A, 4-nonylphenol and 4-tert-octylphenol
[44]. The latter three have micromolar binding affinity whereas
the first three have nanomolar affinity for wild type ER [45].
As a first test we compared the binding affinity of our wt-
ERa
LBD protein with that of the full length ER supplied with the
kit. The binding affinities for the 17b-Estradiol ligand were
measured as 1262 nM and 1664 nM for the full length and wt-
ERa
LBD respectively, indicating that the isolated ligand binding
domain is just as active as the full protein in terms of ligand
binding.
After this control, we measured the binding affinity of the above
mentioned compounds for the recombinant receptors (wt and
mutants; results are shown in Figure 5 and Table 1).
Each compound was tested in a range of 12 concentrations with
the ER receptors (Figure 5). The compounds concentrations (X
Figure 3. Circular dichroism and SDS-PAGE of recombinant ER proteins. CD spectra show typical a-helical character and a single band at the
expected molecular weight is visible (insets). (A) Far-UV CD and SDS-PAGE of wt-ERa
LBD (B) Far-UV CD and SDS-PAGE of M421F-ERa
LBD (C) Far-UV CD
and SDS-PAGE of M421I-ERa
LBD (D) – (F): thermal unfolding data of the three proteins. Intensity of peak at 222 nm plotted as a function of increased
temperature. Melting temperature (Tm) reported.
doi:10.1371/journal.pone.0102658.g003
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Figure 4. Chemical structures of tested compounds.
doi:10.1371/journal.pone.0102658.g004
Figure 5. Competitive binding assay. Competitive binding assay on wt-ERa
LBD (blue squares), M421F-ERa
LBD (red circles) and M421I-ERa
LBD (green
triangles) with six different compounds: 17b-estradiol (panel A), 17a-ethinylestradiol (panel B), bisphenol-A (panel C), tamoxifen (panel D), 4-
nonylphenol (panel E) and 4-tert-octylphenol (panel F).
doi:10.1371/journal.pone.0102658.g005
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axis) were plotted in a logarithmic scale against the Polarization
values (Y axis). The plot of compounds concentrations against
Polarization were fitted with a one site competition four
parameters logistic curve (see Materials and Methods for further
details).
The half maximal inhibitory concentration (IC50) values of the
wt-ERa
LBD towards the selected compounds agreed with literature
data [18,46]. Differences in protein preparation and assay
conditions may contribute to the small variability seen among
literature and present data.
The IC50 of the mutant M421F-ERa
LBD (red circles in Figure 5)
with most compounds was different from the wt-ERa
LBD (blue
squares in Figure 5). In particular, IC50 values indicate that 17a-
ethinylestradiol and bisphenol-A bind approximately 6 times more
strongly to M421F-ERa
LBD than to wt-ERa
LBD (Figure 5 and
Table 1). 17b-Estradiol and 4-nonylphenol bind twice as strong to
M421F-ERa
LBD, as well. No differences were observed for
tamoxifen and 4-tert-octylphenol whose IC50 values are not
significantly different between M421F-ERa
LBD and wt-ERa
LBD
(Figure 5 panels D and F).
Comparing the IC50 values of the mutant M421I-ERa
LBD
(green triangles in Figure 5) with the wt-ERa
LBD (blue squares in
Figure 5) we observe, instead, that in all cases the mutation
negatively affects the binding affinity, with IC50 values between 5
and 20 times higher. The M421L-ERa
LBD gave the same results as
M421I-ERa
LBD and for this reason was not further considered.
Repeated measurements were performed over a 9 months period
with proteins stored at 220uC; the low standard errors suggest
that the proteins are stable, retaining not only their tertiary
structure but also their binding ability for at least 9 months. This is
an encouraging observation about the possibility to use these
receptors as bio-recognition elements in an assay to detect EDCs.
Discussion
The possibility of rationally modify ER receptors with improved
affinities towards different classes of endocrine disrupting chem-
icals would allow both the development of analytical tools for the
rapid screening and detection of EDCs and a better understanding
of the their structure-activity relationship. To this end the
combination of structural analysis and computational modeling
allowed the design of mutants predicted to have different affinities
towards different EDC classes. Indeed, we obtained mutated ERs
with 2 to 6 fold increased binding affinity for 17b-estradiol, 17a-
ethinylestradiol, bis-phenol-A and 4-nonylphenol.
Computational docking simulations suggested that the mutant
M421F-ERa
LBD would have improved binding affinity for at least
some chemical compounds, as it was later verified by experimental
results. Generally speaking, docking results cannot be taken at face
value, especially when comparing binding energies. However, they
do provide useful hints about what is feasible and what not, thus
guiding the rational design of mutants. In the case of M421F-
ERa
LBD, simulations indicated that introduction of an aromatic
side chain could favor binding of aromatic compounds, either
through direct stacking interactions between the aromatic rings of
chemicals and protein side chains or simply by increasing the
overall aromatic content of the ligand binding pocket. It is also
possible that the mutation stabilizes transient intermediates that
facilitate passage of the organic compound from the media to the
buried ligand binding pocket, although we have no direct evidence
for this.
In contrast to the M421F mutation, the M421I restricts the
binding pocket (Isoleucine has a bulkier side chain than
Methionine) without increasing the aromatic content. This reduces
the binding affinities of all the tested compounds by 8 to 20 folds.
The in-silico designed mutants, M421F-ERa
LBD and M421I-
ERa
LBD, were properly folded and active in solution, as shown by
their CD spectra and binding properties. These findings highlight
the advantages of sequence analysis and the use of mutations that
are rare but yet present as natural variants in some species. This
approach highly increases the possibility that the resulting mutants
are properly folded and active, something that is not always
guaranteed when mutants are generated through randomization
technologies or other strategies. As an added bonus, the isolated
ligand binding domain that we used proved to be more stable than
the full-length ER protein used in other published or commercial
assays. Introduction of the rational mutation M421F further
increased protein stability, both in terms of increased resistance to
thermal denaturation (as proved by the increase of the melting
temperature from 60 to 66uC) and of ligand binding activity after
prolonged storage.
The M421F-ERa
LBD with increased stability and higher binding
affinities towards selected EDCs could be used as the capture
agent in affinity chromatography. For example, our recombinant
ERa
LBD receptor was recently used for the fast detection of
estrogens in dietary supplements [47]. In addition, the availability
of ER proteins with variable binding affinities (i.e. wild type,
M421F and M421I mutants) could be used in array format assays
to not only detect EDCs but also to discriminate amongst different
Table 1. IC50 values and standard errors resulting from the competitive binding assay performed in four replicates with wt-ERa
LBD
(column 2), M421F- ERa
LBD (column 3) and M421I- ERa
LBD (column 4) and selected compounds (ligands, column 1): 17b-estradiol,
17a-ethinylestradiol, bisphenol-A, tamoxifen, 4-nonylphenol and 4-tert-octylphenol.
IC50
LIGANDS wt-ERa
LBD M421F-ERa
LBD M421I-ERa
LBD
17b-Estradiol 1664 nM 762 nM 191650 nM
17a-Ethinylestradiol 1266 nM 2.160.9 nM 90621 nM
Bisphenol-A 1162.5 mM 1.960.5 mM 10069 mM
Tamoxifen 47614 nM 55640 nM 8306300 nM
4-Nonylphenol 861 mM 462 mM 60630 mM
4-Tert-octylphenol 11.461.5 mM 1064 mM 200660 mM
The M421F-ERa
LBD shows lower IC50, compared to wt-ERa
LBD, for four compounds (17b-estradiol, 17a-ethinylestradiol, bisphenol-A and 4-nonylphenol) out of six.
The M421I-ERa
LBD has higher IC50, compared to wt-ERa
LBD, for all the tested compounds.
doi:10.1371/journal.pone.0102658.t001
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EDC classes. Moreover, this kind of receptors can be used as bio-
recognition element for label-free detection by means of highly
sensible techniques, such as those based on SPR (Surface Plasmon
Resonance), QCM (Quartz Crystal Microbalance) or MC (Micro
Cantilever) [48]. Such detection systems could be then applied for
the EDC screening in complex matrices such as food, aquaculture,
fresh and seawater as well as for screening of chemicals with
potential EDC activity.
Our results indicate, as a proof of concept, that the combination
of structural and sequence analysis with computational simula-
tions, allow the successful rational design of ER mutants with
desired binding properties. We think that the workflow illustrated
in this manuscript could be successfully applied to the rational
design of other ER mutants or to the modification of other ligand
binding proteins.
Materials and Methods
Materials
The wild-type estrogen receptor a ligand binding domain
encoding gene was synthesized and cloned into pET21a(+) by
Genscript (Piscataway, NJ, USA). The QuikChange Site-Directed-
Mutagenesis Kit was purchased by Qiagen (Hilden, Germany),
while primers and sequencing were done by Primm (Milan, Italy).
The Bacto Yeast Extract and Bacto Tryptone for the Luria
Bertani (LB) medium were from BD Biosciences (Franklin Lakes,
NJ, USA). Rosetta 2(DE3)pLysS Competent Cells come from
Merck.
Isopropyl b-D-1-thiogalactopyranoside (IPTG), Tris-HCl,
NaCl, b-mercaptoethanol (b-Me), 3-(1-pyridinio)-1-propanesulfo-
nate (NDSB) and the test compounds 17b-estradiol, 17a-
ethynilestradiol, bisphenol-A, tamoxifen, 4-nonylphenol and 4-
tert-octylphenol were supplied by Sigma Aldrich.
Nickel HiLoad Column and the AKTA System purifier are
from GE Healthcare. Life Technologies supplied the PolarScreen
Estrogen Receptor-a Competitor Green Assay.
Alignment and Computational analysis
Estrogen receptor protein sequences from several species were
retrieved through the Expasy protein server database (http://
www.expasy.org/). Sequence alignment was performed according
to standard procedures using the Jalview program suite and
included algorithms (http://www.jalview.org/). Duplicate and
incomplete sequences were manually removed from the analysis.
Structural predictions of mutated ER.
The X-ray structure of a human estrogen receptor complexed
with bisphenol-A (PDB: 3UU7) was used as a starting PDB file.
Mutants model structures were predicted by Pymol [49] using the
wild type as a template structure and changing the side chain
conformation according to rotamer libraries. Homology modeling
was performed with the i-Tasser web server [50,51]. The PDB files
of wild type and mutant model structures were prepared for
docking using the dockprep tool in UCSF Chimera package [52],
while bisphenol-A was prepared using MarvinSketch (Marvin
5.9.0, http://www.chemaxon.com/) and OpenBabel [53]. Com-
putational docking was performed by means of SwissDock server
(www.swissdock.ch) based on the docking software EADock DSS
[54], with a user-defined box (15A˚x 15A˚x 15A˚) centered on the
receptor binding site of the LDB. Briefly, a tree-based Dihedral
Space Sampling (DSS) algorithm generates 15000 binding modes
that are subsequently minimized (100 steps of steepest descent
algorithm and 250 steps of adopted basis Newton Raphson
algorithm). Redundant binding modes and binding modes making
little or detrimental interactions with the protein are removed.
Simultaneously, the CHARMM [55] energies of the remaining
binding modes are estimated on a grid. Then, binding modes with
the most favorable energies are ranked, taking account of the
solvent effect using the FACTS implicit solvation model [56], and
clustered by root mean square deviation (RMSD) with a distance
cutoff of 2 A˚. Finally, the most favorable clusters are ranked by an
estimated DG of binding. Selected calculations were repeated with
the docking program Autodock 4.2 [57] with default options and
similar search boundaries as above. Docking was performed either
with rigid or flexible body. The latter option allows for limited
movement of protein side chain and backbone. No significant
differences were noted between the various algorithms. Subse-
quent molecular graphics and analyses of docking results were
performed with the UCSF Chimera package [52], or with Pymol
[49]. 3D structures were analyzed with the program Pymol.
In an attempt to cover the different conformations allowed to
the F421 mutant, we generated four different models in which the
aromatic side-chain occupies four different positions, defined by
either rotamer libraries (using Pymol) or de novo structural
predictions (using the iTASSER server). We then used each of
these models independently in subsequent docking simulations. As
a validation step for our approach we docked EDC/ER complexes
with known experimental structure. Evaluation of the spatial
distance of the ligand position between experimental and
predicted structure (RMSD) showed that solutions nearly identical
to the experimental ones were selected by the computational
algorithm as most energetically favorable. This suggests that the
approach can give reliable information also for complexes with
unknown experimental structure.
Generation of mutated plasmids
In order to selectively mutate the methionine 421 of the wt-
ERa
LBD into phenilalanine, leucine or isoleucine, the plasmid
containing the wild type gene was used as starting material.
To generate the M421F, M421I and M421L variants two
mutagenic primers (forward and reverse) were designed for each
single mutation according to indications on the QuikChange Site-
Directed-Mutagenesis Kit (Qiagen) with a length between 25 and
45 base pairs, Tm$78uC.
Forward Primer M421F: 59- AGGCAAATGCGTC-
GAGGGTTTTGTGGAAATTTTTGACATGC-39
Reverse Primer M421F: 59- GCATGTCAAAAATTTCCA-
CAAAACCCTCGACGCATTTGCCT -39
Forward Primer M421I: 59-GCAAATGCGTCGAGGG-
TATTGTGGAAATTTTTGACATG-39
Reverse Primer M421I: 59-CATGTCAAAAATTTCCACAA-
TACCCTCGACGCATTTGC-39
Forward Primer M421L: 59-ATCAAGGCAAATGCGTC-
GAGGGTCTGGTGGAAATTT-39
Reverse Primer M421L: 59-AAATTTCCACCAGACCCTC-
GACGCATTTGCCTTGAT-39
Each reaction volume contained the reaction buffer, plasmid
pET21a(+)-wt-ERaLBD, the two primers, dNTP mix, and water.
The PFU-Turbo polymerase (QuikChange Site-Directed-Muta-
genesis Kit, Qiagen) was added and the PCR reaction was
performed in a PCR Thermocycler (Stratagene). After the PCR,
the DpnI enzyme (Qiagen) was added to digest the parent DNA
and then the mixture was used to transform XL1Blue competents
cells (Qiagen). The extracted plasmids from the positive colonies
were sequenced (Primm).
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Protein expression and purification
The pET21a(+) plasmid containing the ER gene was used to
transform Rosetta 2(DE3)pLysS Competent Cells (Merck), plated
on ampicillin selective LB-agar and incubated over night at 37uC.
Different E.coli strains, such as One Shot BL21 Star (DE3),
Rosetta 2(DE3) and Rosetta 2(DE3) pLysS were tested and the
latter ones were chosen because they showed the best yield in
terms of purity and amount (mg/l culture) of the expressed protein
due to the pLysS plasmid that expresses T7 lysozyme [58].
The cells are then grown in liquid culture (LB with 10% sucrose)
at 37uC until an OD600 of 0.7 is reached, then IPTG 0.5 mM and
3% ethanol are added. The protocol was modified starting from
the one of Ahrens et al. [59]. Afterwards cells are grown at 18uC
for 18 hours; washed once in buffer A (50 mM Tris-HCl, 50 mM
NaCl, 10 mM b-mercaptoethanol, 10 mM ((3-(1-pyridinio)-1-
propanesulfonate), 1 tablet of complete protease inhibitor, and
20 mM imidazole), then sonicated and centrifuged at 18000 rpm
for 1 h at 4uC. The supernatant is then loaded on a 5 mL Nickel
HiLoad Column (GE Healthcare) connected to an AKTA system
purifier while the pellet was resuspended in Tris-HCl 50 mM
pH 7.5 and Urea 6 M (5 mL per liter of culture) to extract
additional proteins from the cell debris and left reacting for 5
minutes, then centrifuged at 18000 rpm for 1 h at 4uC.
The Nickel HiLoad column is equilibrated with washing buffer
1X (50 mM Tris-HCl pH 7.5, 500 mM NaCl, 20 mM imidazole,
10 mM b-mercaptoethanol) prior to supernatant loading. After
washing out the unbound proteins with 4 column volumes
(20 mL), the elution of the His-tagged protein is performed by a
linear gradient from 0 to 100% of elution buffer (50 mM Tris-HCl
pH 7.5, 300 mM NaCl, 500 mM imidazole, 10 mM b-mercap-
toethanol). The fractions that absorb at 280 nm are run on a SDS-
PAGE gel to visualize the presence of the protein.
The purified fractions containing the protein are dialyzed in
storage buffer (Tris-HCl 20 mM pH 7.4 and NaCl 150 mM) to
remove the imidazole and to lower the salt concentration. The
purified protein was then stored at 220uC.
Protein characterization with Circular Dichroism (CD)
spectroscopy
Circular dichroism spectra were recorded with a J750 Circular
dichroism spectrometer from Jasco interfaced with a Peltier
temperature control unit with 1 mm path length cuvette. Analysis
of the far-UV region (185–260 nm) was used to investigate the
secondary structure and the folding of the protein. CD spectra
were analyzed with the DichroWeb [39] online software, by means
of the CDSSTR program [60]. Thermal denaturation experi-
ments were performed by monitoring the circular dichroism at
222 nm while changing the temperature from 25 to 90uC (1uC/
min) and backward. Reference spectra were collected for the
buffers in which proteins were dissolved. Denaturation curves were
analyzed assuming a two-state unfolding model and melting
temperature (Tm) was calculated for every mutant [61]. All the
statistical analysis and fittings were performed with Sigma Plot
12.3.
Competitive binding assay
To test the binding affinity of the recombinant receptor for
EDCs we used the competitive binding assay developed by Life
Technologies for ERa, the PolarScreen Estrogen Receptor-a
Competitor Green Assay. Although radioactive binding assays are
widely used for ER, fluorescence assays are just as reliable but do
not require radioactive safety procedures making them more
convenient.
The full length ERa provided with the kit was replaced by our
recombinant ERa
LBD. In short, wt or mutant ERa
LBD are added to
the Fluormone and incubated at 4uC for 45 minutes to form the
receptor-Fluormone complex. This complex is then mixed and
incubated at 25uC for 2 h with the individual EDCs and the
intensity of the fluorescence polarization signal (directly propor-
tional to the amount of Fluormone bound to the protein)
measured. The addition of competitors displaces the Fluormone
from the ERa
LBD receptor, resulting in a decreased fluorescence
signal. The fluorescence polarization anisotropy signal (P) is read
using an Infinite 200 Pro multimode plate reader from Tecan and
calculated with the following equation:
P~ FE{F\ð Þ= FEzF\ð Þ
Where:
FI= Fluorescence intensity parallel to the excitation plane,
F ) = Fluorescence intensity perpendicular to the excitation
plane.
The P data (y) were fitted against the competitor concentrations
(x) with a typical one site competition three parameters logistic
curve:
y~minz max{minð Þ= 1z10x{LogIC50  
Where:
min and max are respectively the minimum and maximum
polarization values, LogIC50 = Log of the concentration of test
compound required to reduce the maximum polarization value by
50%. All the resulting IC50 values are obtained by the average of
at least four different experiments.
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